Oncology

The senior vice president of Technical Operations at Senti Biosciences discussed the company’s NK cell logic-gating platform and allogeneic approach.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Phil Cyr, Senior Vice President, Precision Value & Health, discussed challenges to tackle with CAR T-cell therapies.

Hong Ma, senior vice president, clinical development, cancer immunotherapy, CARSgen, discussed data from a phase 1 trial of CT041.

The chief medical officer of Triumvira Immunologics discussed how TAC01-HER2 could address unmet needs in treating solid tumors.

Verismo plans to begin enrollment in the STAR-101 trial in the first quarter of 2023.

The deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.

Review top news and interview highlights from the week ending September 23, 2022.

Interim data showed a 78% overall response rate and a 67% complete response rate.

Eleven patients in the LUMMICAR-2 trial were evaluable for preliminary efficacy analyses.

The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has cleared the investigational new drug application for AB-201.

The grant will specifically help support the trial’s treatment arm for patients with post-transplant acute myeloid leukemia with minimal residual disease.

The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.

Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.

Hong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.

Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.

Review top news and interview highlights from the week ending September 16, 2022.

A single-center study assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.

The announcement comes after positive top-line results in the ongoing KarMMa-3 study.

MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.

The FDA authorized the natural killer cell therapy combo for compassionate use.

Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.

The 5-year relapse-free survival rate was 22.3% with T-VEC prior to surgery, compared with 15.2% for surgery alone.

Of the 8 treated patients who were evaluable, 6 patients had stable disease at Day 28.

Based on the findings, investigators are considering registration with the FDA and EMA.

ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.